RESEARCH IN PULMONARY HYPERTENSION
"PHA's research program has yielded an explosion of understanding about PH that was not known before."
- John Newman, MD, Vanderbilt University Medical Center
Twenty years ago there were no pulmonary hypertension treatments available. Through focused research there are now twelve PH-specific treatments with more in development. But we know that your ultimate wish is for a cure, and that is why PHA will continue to support the work of researchers until the day when no one suffers from PH.
PHA’s Research Program
In just a little under a decade, PHA’s Research Program has committed more than $12.5 million for PH research by leveraging partnerships with the National Heart, Lung, and Blood Institute (NHLBI) and the American Thoracic Society (ATS). We have supported over 49 promising researchers through four independently reviewed, cutting-edge research programs.
Read more about PHA’s Research Program
PHA’s Scientific Leadership Council’s Education Committee has put together comprehensive factsheets on all the treatments available for pulmonary hypertension. Read more about current treatments
Research Corner in Pathlight
Every issue of PHA’s quarterly print newsletter Pathlight features a Research Corner with information about some of the latest research. Read more
Pulmonary Hypertension Research News
What Do You Want from New PAH Drugs?
The Food and Drug Administration is making changes in how they approve drugs. For the first time ever, they are asking, “What do patients want from new drugs?”
Hundreds of disease communities have asked for a chance to answer that question. PAH is one of only sixteen diseases selected by the FDA for this discussion. Please help us make a better tomorrow for PAH patients by attending in person or listening in and submitting comments via webcast on May 13.
Take these two steps to RSVP for this exciting opportunity:
- Register with the FDA. Whether you are attending in person or by webcast, you must register on FDA’s website. All members of the PH community are welcome, but PAH patients and parents of young patients will do the talking.
- Claim your seat on the bus. For those who would prefer not to drive to the FDA campus, buses are available from Maryland, New York and Philadelphia. Complete this form to claim your seat on the bus.
Friday, March 21, 2014 10:00:00 AM
Yale Study Offers Insight Into Function of Cells Linked to PH
Science Codex - Most of us draw roughly 25,000 breaths a day without any thought. But for patients with pulmonary hypertension, a life-threatening increase in blood pressure in the lungs, even the smallest task can leave them gasping for air. A new study by researchers at Yale School of Medicine offers insight into the function of cells linked to this incurable and often fatal illness.
Thursday, March 20, 2014 11:22:00 AM
Improved Right Heart Imaging Approved by FDA
The Food and Drug Administration (FDA) has approved a device called the VMS™ heart analysis system which can be used in echocardiography allowing your physician to better measure right heart volumes and function.
Thursday, March 13, 2014 3:55:00 PM
Meet the Barst Pediatric Research Fund Awardees
In 2012, PHA established the Robyn J. Barst Pediatric PH Research and Mentoring Fund in memory of Dr. Barst, a pioneer in the field of pediatric pulmonary hypertension research and treatment.
On May 27, 2014, the 2014 grantees, Dr. Mehdi Fini and Dr. Melanie Nies, will discuss their research and the potential applications for pediatric PH treatments in this live webinar.
Dr. Mehdi Fini has been awarded the Cordelia's Pediatric Mentoring and Research Grant through the Barst Fund.
Dr. Melanie Nies has been awarded the Matthew and Michael Wojciechowski Pulmonary Hypertension Pediatric Proof-of-Concept Grant through the Barst Fund.
Register now for the webinar!
Want to learn about the Barst Fund Awardees early? Read their interview on PH Kids | Read more information on the Barst Fund
Tuesday, March 04, 2014 4:46:00 PM
Discovery of Genetic Mutations that Cause PCH
A team of researchers, led by physicians and scientists at Intermountain Healthcare's Intermountain Medical Center and ARUP Laboratories, has made a medical breakthrough by discovering genetic mutations that cause a rare and deadly lung disease.
The disease, pulmonary capillary hemangiomatosis or PCH, is a rare cause of pulmonary hypertension, which occurs predominantly in young adults. PCH affects less than one in a million people, and has been extremely difficult and expensive to diagnose, as well as challenging to treat. Read PHA's full release
Tuesday, February 11, 2014 9:20:00 AM